Your browser doesn't support javascript.
loading
Predictors of objective treatment adherence in adolescents with epilepsy: The important role of motivation.
Lang, Amy C; Stevens, Jack; Mara, Constance A; Patel, Anup D; Schmidt, Matthew; Tenney, Jeffrey R; Modi, Avani C.
  • Lang AC; Cincinnati Children's Hospital Medical Center, United States. Electronic address: amy.lang@cchmc.org.
  • Stevens J; Nationwide Children's Hospital, United States. Electronic address: jack.stevens@nationwidechildrens.org.
  • Mara CA; Cincinnati Children's Hospital Medical Center, United States; University of Cincinnati, United States. Electronic address: constance.mara@cchmc.org.
  • Patel AD; Nationwide Children's Hospital, United States. Electronic address: anup.patel@nationwidechildrens.org.
  • Schmidt M; University of Florida, United States. Electronic address: matthew.schmidt@coe.ufl.edu.
  • Tenney JR; Cincinnati Children's Hospital Medical Center, United States; University of Cincinnati, United States. Electronic address: jeffrey.tenney@cchmc.org.
  • Modi AC; Cincinnati Children's Hospital Medical Center, United States; University of Cincinnati, United States. Electronic address: avani.modi@cchmc.org.
Epilepsy Behav ; 142: 109192, 2023 05.
Article en En | MEDLINE | ID: mdl-37068420
OBJECTIVE: Adolescents with epilepsy are at heightened risk for suboptimal anti-seizure medication (ASM) adherence; however, there is a paucity of adherence interventions for this age group. The current study aimed to identify a comprehensive and novel set of predictors of objective, electronically-monitored ASM adherence in adolescents with epilepsy. METHODS: Participants included 104 adolescents (13-17 years old; M = 15.36 ± 1.40), diagnosed with epilepsy and their caregivers. Cross-sectional data were collected from adolescents, caregivers, healthcare providers, and medical chart reviews, including demographics (i.e., age, race/ethnicity, sex, insurance status), the COVID-19 pandemic (i.e., participation before versus during), seizure characteristics (i.e., presence and severity), ASM side effects (Pediatric Epilepsy Side Effects Questionnaire), adherence motivation (1-item 6-point Likert scale item), and adherence barriers (Pediatric Epilepsy Medication Self-Management Questionnaire). Electronically-monitored adherence data was collected via the AdhereTechTM pill bottle or the Vaica SimpleMedTM pillbox over 30 days. RESULTS: Adolescents demonstrated suboptimal adherence at 78 ± 31.6%, despite high ASM adherence motivation (M = 4.43 ± .94) and minimal adherence barriers (M = 35.64 ± 3.78). Hierarchical multiple regression, which included non-modifiable sociodemographic and medical variables (Block 1) and behaviorally modifiable psychosocial variables (Block 2) was significant, F(12,87) = 3.69, p < .001. Specifically, having private insurance (versus Medicaid or public insurance; t = -2.11, p = .038) and higher adherence motivation (t = 2.91, p = .005) predicted higher objective ASM adherence. CONCLUSION: Routine assessment of adherence predictors is vital for the promotion of adherence among adolescents with epilepsy. Adolescent adherence motivation may be an important element of multi-component interventions focused on improving ASM adherence in adolescents with epilepsy.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Epilepsia / COVID-19 Tipo de estudio: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Child / Humans Idioma: En Año: 2023 Tipo del documento: Article